yr (25) . Delayed initiation of therapy likely represents late diagnosis in some patients and failure to initiate therapy promptly after diagnosis in others. Such treatment delay has a number of potential negative consequences including progressive growth failure and delayed induction of puberty in an attempt to maximize adult height, which in turn may impact psychosocial function, bone mineralization, and cardiovascular health. Earlier diagnosis of TS is key to optimizing patient outcomes. However, in the absence of data from well-controlled clinical trials, it has been unknown whether early initiation of GH treatment in very young girls with TS can prevent subsequent growth failure. Therefore, the primary goal of this prospective, randomized, controlled, multicenter trial was to determine whether the ongoing growth failure that typically occurs in the first few years of life in girls with TS could be prevented or corrected by early GH treatment. In addition, to understand the variability of the GH treatment response, we evaluated factors associated with the magnitude of response and determined whether this could be predicted in a clinically useful way.
Subjects and Methods
Subjects were recruited from endocrine clinic and primary care referral populations, the Turner Syndrome Society of the United States and through website advertising (www.turner-syndrome-us.org; www. magicfoundation.org; www.hgfound.org; www.centerwatch.com). Criteria for study entry were: age 9 months to 4 yr; karyotype-proven TS; normal urinalysis, hemoglobin, and TSH; adequate thyroid hormone replacement for at least 6 months in those with hypothyroidism; and written informed consent from legal guardian(s). Exclusion criteria were presence of any Y-chromosomal component in the karyotype in subjects with gonads in situ, autosomal abnormality, concurrent treatment that might influence growth, and clinically relevant systemic illness. There were no specific eligibility criteria based on height or height velocity.
Study design
This prospective, randomized, controlled, 2-yr, open-label study conducted between August 1999 and August 2003 was approved by the ethics review boards of the 11 participating institutions in the United States and performed in accordance with the ethical principles of the Declaration of Helsinki. Eligible subjects were stratified into two groups based on age at study entry (9 months to 2.5 yr; Ͼ2.5 to 4 yr), and then, using a blinded phone-in process, were randomized in a 1:1 ratio to either a GH treatment group or a nontreatment control group. After a detailed baseline evaluation, subjects were followed at approximately 4-monthly intervals for 2 yr.
Treatment intervention
The GH group received daily sc injections of 50 g/kg of GH (Humatrope; Eli Lilly and Co., Indianapolis, IN); the control group received no injections. Treatment compliance was assessed by review of study diaries and returned drug cartridges. Subjects were judged as compliant if they received at least 80% of their scheduled GH injections.
Efficacy measures
The primary outcome measure was linear growth, as measured by change in sd score (SDS) for length or height (depending on age), from baseline to 2 yr. A height gain of at least 0.5 SDS was designated as clinically significant. Age-appropriate measurements were obtained at each visit for length, using an infant-measuring box (children Ͻ2 yr of age or older children for whom accurate standing measurements could not be obtained), and/or height, using a standard wall-mounted stadiometer (children older than 2 yr). Because of the overlap in U.S. normative datasets for infancy and childhood, both length and height were measured for girls aged between 2 and 3 yr. If a child had both length and height measurements at the same study visit, the length measurement was used in the analyses.
Length or height SDS values (hereafter referred to as height SDS even if length was measured) were calculated on the basis of data for agematched girls from the U.S. Centers for Disease Control (27) . Midparental (or target) height (MPH) was calculated as follows: (father's height Ϫ 13 cm ϩ mother's height)/2 (28) and converted to SDS using normative height data for women at 20 yr of age (27) .
Laboratory data and radiology
Standard hematological and clinical chemistry tests were performed at baseline. Serum IGF-I, IGF-binding protein-3 (IGFBP-3), and bone turnover markers (N-telopeptide X and amino-terminal propeptide of type I collagen) were measured at baseline, 4 months, 1 yr, and 2 yr. IGF-I and IGFBP-3 assays were performed by Esoterix Endocrinology (Calabasas Hills, CA); SDS were calculated using Esoterix's data for healthy controls. Bone turnover markers were measured at the University of Connecticut (Hartford, CT). Measurements of TSH and FSH were performed using standard assays at baseline, 1 yr, and 2 yr [FSH results have been reported (29) ]. For girls with nonmosaic karyotypes whose families consented, parental origin of the X chromosome (maternal vs. paternal) was determined by DNA microsatellite analysis (Greenwood Genetics, Greenwood, SC). All analyses were performed at central laboratories.
Bone age x-rays (left wrist and hand) obtained at baseline, 1 yr, and 2 yr were read according to the standards of Greulich and Pyle (30) by two independent readers blinded to all subject information and reported as the average of the two readings.
Safety measures
Safety was assessed at each visit based on reported adverse events, detailed history, and physical examinations. In addition, because girls with TS are at increased risk for a variety of health problems, information regarding specific, relevant medical conditions was obtained by targeted collection on the case report forms. Furthermore, because of the increased risk of otitis media and hearing loss in girls with TS, a thorough assessment of ear disease, including measurements of middle ear function by tympanometry, was performed at each visit, and formal audiometry was performed annually.
Statistical methods
The primary efficacy analysis, prespecified in the protocol, was conducted on the baseline-to-2 yr change in height SDS for all subjects who had measurements at both time points, using an ANOVA model with treatment group and baseline age group as explanatory variables. The between-treatment group differences in height SDS at baseline and at each post-baseline visit were also analyzed using this model. A secondary analysis was performed with data for all subjects who had at least one post-baseline measurement, including those who did not complete the study, using a repeated-measures mixed model to assess betweengroup differences for change in height SDS from baseline to each postbaseline visit. The model used a heterogeneous variance structure such that the variance was allowed to differ within each age group. Weight SDS and body mass index (BMI) (kg/m 2 ) at baseline, at each visit, and at the 2-yr endpoint and the changes in these variables from baseline to each post-baseline visit were compared between treatment groups using the ANOVA and repeated-measures models described above.
For analyses of changes in height SDS, one-sided tests were used with the significance level set at 0.05. All other analyses of efficacy variables were conducted using two-sided tests with the significance level set at 0.05.
To determine factors contributing to the variability of response to GH, correlations between the outcome variables (2-yr height SDS and baseline-to-2-yr change in height SDS) and baseline or treatment-related variables were examined using the Pearson correlation coefficient. In addition to variables with significant univariate correlations, a number of clinically relevant baseline and on-study variables were then used to develop multiple linear regression models to determine whether an individual subject's response to GH (2-yr height SDS or baseline-to-2-yr change in height SDS) could be predicted in a clinically useful manner. Model selection was based on the complexity of the model, assessment of model bias (Mallow's Cp statistic), and the predictive performance [predicted residual sum of squares (PRESS) statistic] of the model. For comparison, models were also developed for the untreated group (data not shown).
Serious adverse events, treatment-emergent adverse events, and laboratory data were summarized for all subjects who entered the study.
Analyses were performed using SAS software (version 8.2; SAS Institute, Inc., Cary, NC). Data are reported as mean Ϯ 1 sd, unless noted otherwise.
Results
Eighty-nine girls aged 9 months to 4 yr (24.0 Ϯ 12.1 months) were randomized to a nontreatment control group (n ϭ 44) or a GH treatment group (n ϭ 45) ( Table 1) . After study entry, one control subject was found to have a 46,XX karyotype; her data were excluded from the efficacy analyses but are included in the safety analyses. Karyotype distribution was as follows: 45,X karyotype was present in 29 of 43 (67%) control subjects and 27 of 45 (60%) GH-treated subjects; 45,X/46,XX karyotype was present in 7 of 43 (16%) control subjects and 7 of 45 (16%) GH-treated subjects; the remaining subjects 7 of 43 (16%) controls and 11 of 45 (24%) GH-treated subjects] had a variety of other karyotypes. Of 35 subjects with nonmosaic karyotypes whose families agreed to participate in testing for parental origin of the X chromosome, 29 (83%) had maternal X chromosomes and six (17%) had paternal X chromosomes.
Seventy-nine of the 89 randomized subjects completed the 2-yr study (control n ϭ 38 of 44, including the subject with 46,XX karyotype; GH n ϭ 41 of 45). Reasons for discontinuation were as follows: for the control group, parents' decisions (n ϭ 2), scheduling problems (n ϭ 1), request for GH treatment (n ϭ 2), and lost to follow-up (n ϭ 1); for the GH group, relocation (n ϭ 1) and lost to follow-up (n ϭ 3). Compliance with GH treatment was generally excellent; 95% of subjects received at least 80% of their scheduled injections.
On average, subjects received 95% of their total scheduled injections, but there was substantial interindividual variability in overall compliance (range, 75-100%).
GH corrected growth failure and restored height to the normal range
Early GH treatment corrected growth failure and promoted catch-up growth in this cohort of under-4-yr-old girls with TS; the control group had progressive growth failure, with height falling by an additional 0.5 Ϯ 0.5 SDS from Ϫ1.8 Ϯ 1.1 (baseline) to Ϫ2.2 Ϯ 1.2 (2 yr), whereas mean height of the GH group increased by 1.1 Ϯ 0.6 SDS, from Ϫ1.4 Ϯ 1.0 (baseline) to Ϫ0.3 Ϯ 1.1 (2 yr) ( Fig. 1) . Thus, the between-group difference for change in height SDS after 2 yr was 1.6 Ϯ 0.6 (P Ͻ 0.0001). This analysis was performed on data from the 78 subjects with karyotype-proven TS who completed the 2-yr study. A sensitivity analysis using a repeated-measures mixed model with data for all 87 subjects who had at least one post-baseline measurement (including nine subjects who discontinued before study completion) also demonstrated a significantly greater post-baseline increase in height SDS for the GH group [between-group difference (least squares mean Ϯ se), 1.03 Ϯ 0.09 SDS; P Ͻ 0.0001].
The GH treatment effect was rapid; the between-group difference in height SDS was significant by 4 months and increased progressively ( The data exclude one subject who was found after study entry to have a 46,XX karyotype. Data shown are mean Ϯ 1 SD. There were no significant differences between treatment groups at baseline. a Baseline bone age missing for two subjects in each group. b Father's height missing for one GH subject at both baseline and endpoint. c Baseline data missing for one subject in each group; one control subject had an erroneous value at baseline, so the value was not used; endpoint data missing for two control subjects.
d Baseline data missing for eight control subjects and three GH-treated subjects; endpoint data missing for four control subjects and seven GH subjects.
year GH, 0.70 Ϯ 1.11, P Ͻ 0.0001). Total 2-yr height gain was 13.6 Ϯ 3.5 cm for the control group compared with 20.4 Ϯ 3.3 cm for the GH group (P Ͻ 0.001).
The GH treatment effect was also evident when the heights of control and GH-treated subjects were compared with U.S. standards (27) . Control subjects had progressive decreases across the height percentile channels, whereas the heights of all but three of the GH-treated subjects were restored within the normal channels ( Fig. 2) . Two-year GH-induced height gain was between 0.0 and ϩ1.0 SDS for 21 of 41 (51%) subjects, between ϩ1.0 and ϩ2.0 SDS for 14 of 41 (34%), and more than ϩ2.0 SDS for five of 41 (12%). At the 2-yr time point, only 7% of GH-treated subjects remained below Ϫ2.0 SDS (ϳ2.3rd percentile); in contrast, 57% of the controls were below Ϫ2.0 SDS at 2 yr (P Ͻ 0.0001). In parallel with the increases in height SDS, GH-treated subjects had significantly greater increases in weight SDS than did control subjects. However, because of the significantly greater height gains in the GH group, there was negligible between-group difference in BMI ( Table 1) .
Effect of GH treatment on bone age
Baseline bone age was similar to chronological age in this young cohort (bone age of 1.92 Ϯ 0.92 yr vs. chronological age Table 1 ). During the 2-yr study, bone age fell behind chronological age for control subjects, whereas there was a small advance for GH-treated subjects (bone age minus chronological age at 2 yr: control, Ϫ0.64 Ϯ 0.80 yr; GH, 0.21 Ϯ 0.96 yr).
Effect of GH treatment on IGF-I and IGFBP-3
Mean IGF-I SDS was Ϫ0.31 Ϯ 0.89 at baseline for the total subject group (Table 1) . Baseline-to-2 yr changes in IGF-I SDS were Ϫ0.09 Ϯ 0.87 for controls and 1.53 Ϯ 0.93 for the GH group. Although IGF-I values were above ϩ2.0 SDS for 37% of GH-treated subjects on at least one post-baseline measurement, no subject had elevated IGF-I SDS at all visits (Fig.  3A) . GH-related changes in IGFBP-3 paralleled IGF-I changes, such that there was a significant correlation between on-treatment values for the two peptides at each post-baseline measurement (at 4 months, r ϭ 0.63, P Ͻ 0.0001, n ϭ 39; at 1 yr, r ϭ 0.80, P Ͻ 0.0001, n ϭ 36; at 2 yr, r ϭ 0.59, P ϭ 0.0004, n ϭ 31; Fig. 3B ). At 2 yr, only one subject had a value that fell within the hypothetical risk profile of an IGF-I SDS in the upper tertile with an IGFBP-3 SDS in the lower tertile (31) (32) (33) (34) (35) .
Factors affecting GH response
GH treatment corrected growth failure and promoted catch-up growth in the treated group as a whole; however, the magnitude of the individual treatment effect varied. Changes in height SDS ranged from a decline of 0.6 SDS in one girl whose treatment compliance was among the lowest to gains of more than 2.0 SDS in five girls who started treatment quite early (between 15 and 27 months) and were more than 90% compliant. There was a modest, but significant, Although baseline height SDS differed somewhat among karyotype groups (45,X: Ϫ1.55 Ϯ 1.02; 45,X/46,XX: Ϫ0.93 Ϯ 1.35; other: Ϫ1.42 Ϯ 0.65), the difference was not statistically significant (P ϭ 0.35), and karyotype had no significant effect on outcome (Fig. 4) . The average 2-yr height gain was somewhat lower for the 45,X group (primarily because of the poorly compliant subject described above), but height gains were significant for each karyotype group ( To determine other factors associated with magnitude of response, we evaluated correlations between baseline and on-study variables and outcomes (both 2-yr height SDS and baseline-to-2-yr height SDS gain; Tables 2 and 3 ). The baseline variable most strongly associated with 2-yr height SDS was baseline height SDS (r ϭ 0.83, P Ͻ 0.0001), which explained almost 70% of the variance in attained height at 2 yr. In contrast, the variable that correlated most strongly with baseline-to-2-yr height SDS gain was the difference between MPH SDS and baseline height SDS, which explained about 10% of the variance (r ϭ 0.32, P ϭ 0.04), suggesting that subjects with the greatest height deficit relative to their genetic height potential may have greater catch-up growth. Not surprisingly, the on-study variable that correlated most strongly with height gain was first-year height velocity, which explained about 15% of the variance in 2-yr height SDS gain (r ϭ 0.39, P ϭ 0.01).
Prediction of response to GH
To predict treatment outcomes, a number of regression models were developed using various combinations of baseline and on-study variables. Significant models were devel-oped for height SDS at 2 yr and 2-yr height SDS gain that may be useful depending on clinical circumstances and available data ( Table 4 ). The most powerful predictor of height SDS at 2 yr was baseline height SDS, and all multivariate models required inclusion of baseline height SDS for significance. Inclusion of one or more additional baseline variables alone or in combination, such as the difference between bone age and chronological age, MPH SDS, IGF-I SDS, and IGFBP-3 SDS improved the predictive power of the models modestly (R 2 values of 0.72-0.75 for two-variable models). In addition, two robust models were developed using four baseline variables each (R 2 ϭ 0.81, P Ͻ 0.0001; Table 4 ).
Not surprisingly, inclusion of one or more variables reflecting initial treatment response (such as 4-month or 1-yr height velocity and 4-month or 1-yr IGF-I or IGFBP-3 SDS) substantially improved the predictive power of the models, such that R 2 values up to 0.86 were obtained with fourvariable models. Notably, the models using 4-month treatment variables were as robust as those that included 1-yr variables, indicating that the initial treatment response is a good predictor of 2-yr response.
The models were less accurate in predicting 2-yr height SDS gain than actual height SDS, and no model was significant without inclusion of height velocity.
Safety analyses
No new or unexpected safety signals associated with GH treatment were detected, and no subject discontinued because of an adverse event. Serious adverse events were reported for four of 44 (9%) girls in the control group (one subject each was hospitalized for surgical repair of an atrial septal defect, croup/ bronchiolitis, gastroenteritis, and dehydration) and four of 45 (9%) girls in the GH group (one subject each was hospitalized for gastroenteritis/dehydration, bacterial pneumonia, persistent bleeding after tonsillectomy, and hypoxemia after adenoidectomy). Treatment-emergent adverse events (events or conditions that began or worsened after study entry) were reported for 43 of 44 (98%) of controls and 42 of 45 (93%) of GH-treated girls. Many of these events were related to ear disorders. There was no detrimental effect of GH treatment on frequency of episodes of otitis media, rates of ear tube insertion, middle ear function, or hearing. Most other events reported with a high frequency were typical childhood illnesses (e.g. fevers, infections, colds, and gastrointestinal disorders), considered unlikely to have been related to GH treatment. There were no significant changes or between-group differences in serum TSH.
Discussion
GH therapy was approved for use in girls with TS by the U.S. Food and Drug Administration in 1996 on the basis of four studies that included girls whose average ages at study entry ranged from 9.1-10.3 yr (10 -12, 14) . Since then, the efficacy of GH treatment for improving short-and long-term growth and adult height in school-aged girls with TS has become even better established (9, 13, 15-17, 36 -38) . Although the Food and Drug Administration approval did not mandate a specific chronological age for initiation of GH therapy in TS, pediatric endocrinologists seem to have been reticent to start GH early. Al- though the reticence in specific cases may be due to factors such as family fears of giving injections, pressing medical/surgical issues, or significant developmental/behavioral concerns, it is likely that the major cause has been the absence of efficacy and safety data in very young girls. This is unfortunate, because growth failure may be quite profound in infancy and the toddler years. Indeed, in one study of longitudinal data for under-8 yr olds with TS, height of 50% of the girls fell below the fifth percentile of the population standard at a mean age of 18 months (22) . Although GH treatment data have been reported for small numbers of preschool-aged girls (13, 36, 39) , no randomized, nontreatment controlled study has evaluated the role of GH in correcting the growth failure that typically occurs in the first few years of life in girls with TS; the study reported here addresses this gap. In this large-scale, multicenter trial, 2 yr of GH treatment initiated between 9 months and 4 yr of age prevented ongoing growth failure and restored height to within the normal range for 93% of girls before 6 yr of age. Compared with girls who received no treatment, whose height SDS continued to decline, GH-treated girls demonstrated rapid, highly significant increases in height velocity and height SDS. As a result, after 2 yr, there was a 1.6 SDS (6.8 cm) between-group difference in height gain, and mean height of the GH-treated group was very close to average for the general population of the same age (Ϫ0.3 SDS).
Early normalization of height has a number of potential ben-efits for young girls with TS, including prevention of staturerelated juvenilization and mascotism, improvement in peergroup integration, reduction of the gap that must be bridged between height at treatment initiation and genetic target height, and the opportunity to initiate estrogen replacement at a physiologically appropriate age (11, 18, 19, 37, 38) . Many studies of GH treatment in girls with TS have established the importance of age at treatment initiation for long-term height gain (12) (13) (14) (15) (16) (17) (18) 39) . Furthermore, the magnitude of the prepubertal height gain appears to be a key determinant of overall height attainment (17) . No previous randomized trial has studied patients as young as our cohort, although a single-arm, observational study in 29 girls with TS aged between 1.4 and 5.9 yr (mean 4.3 yr) provides some comparative data (39) . Height gain after 2 yr was about 1.0 SDS, similar to the 1.1 SDS gain in our 2-yr study. However, the absence of a control group in the observational study likely underestimated the efficacy of GH treatment because the overall impact of GH treatment represents the combined effect of preventing ongoing growth failure (evidenced by further height SDS decline in our controls) and promoting catch-up growth. Thus the overall 2-yr treatment effect (prevention of ongoing growth failure plus catch-up growth) in our study was 1.6 SDS.
Although we found no correlation between age at start of GH treatment and height gain (likely because of limited age range and treatment duration), age and bone age were nevertheless significant factors in a number of height prediction models developed in this study, as also reported by others (17, 25) . Age dependency of GH responsiveness (40) is hypothesized to reflect the decline in proliferative capacity of growth plate chondrocytes with increasing age-the concept of programmed growth plate senescence (41, 42) . Whereas initial reports indicated normal linear growth during the preschool years in girls with TS (3, 4) , more recent studies demonstrate early-onset growth failure in the first few months and years of life (8, (21) (22) (23) (24) . Given this finding, guidelines for care of individuals with TS, which previously recommended that "initiation of GH therapy should be considered as soon as a patient with TS has dropped below the fifth percentile of the normal female growth curve" (43) , have been revised, and the updated guidelines state that "treatment with GH should be considered as soon as growth failure (decreasing height percentiles) is demonstrated and its potential risks and benefits have been discussed with the family" (44) . Unfortunately, because many patients with TS are not diagnosed until mid-childhood, adolescence, or even adulthood (20, (45) (46) (47) , the opportunity to improve height remains limited for many patients. Consequently, a concerted effort is required to enable earlier diagnosis for girls with TS (18, 24, 45, 47, 48) .
Although the overall efficacy of GH treatment in TS is now well established, there is significant variation in individual pa-tient responsiveness to treatment (12-16, 36, 37) . Consequently, the clinician considering GH treatment for a child with TS has limited ability to provide the family with expectations for potential treatment outcome. To address this clinical challenge, investigators have evaluated factors that correlate with the GH treatment response. In addition to age at treatment initiation and GH dose, other baseline factors reported to influence outcome positively include MPH (reflecting genetic height potential), baseline height and weight SDS, bone age delay (13, 17, 25) , presence of a retained maternal (vs. paternal) X chromosome (49) , and presence of the short (exon 3-deleted) form of the GH receptor (50) . Using these findings, various models have been developed to predict height achieved or gained after GH treatment (13, 15, 17, 25) . Notably, although baseline variables are adequate for modest prediction of initial treatment response, prediction of response after the first year requires inclusion of a variable that reflects initial response (e.g. first-year height velocity or change in height velocity from baseline) (13, 25) . Similarly, we found that the models had substantially greater predictive power when a variable reflecting initial treatment response was included. The key conclusion from these analyses is that although it may be possible to predict a portion of the response before initiating treatment, even the best baselinevariable-only models cannot predict response to GH with the degree of accuracy necessary for clinical decision making on an individual patient basis. An additional key point from these regression analyses is that baseline height SDS had negligible influence on the magnitude of the height gain, indicating that the opportunity for GH-induced catch-up growth is similar irrespective of height at treatment initiation. Therefore, a GH treatment trial is probably warranted in most patients with TS who have evidence of growth failure, whether in infancy or later in childhood. In summary, this randomized, controlled clinical trial demonstrates that the growth failure typical of early childhood in girls with TS can be corrected when GH treatment is initiated by four years of age. These findings underscore the importance of early diagnosis of TS and prompt referral to a pediatric endocrinologist for assessment of the many physical and developmental problems that may be associated with this condition, including growth failure. In general, the younger the patient is at GH initiation, the smaller the height deficit to be bridged and the faster height is normalized. Early restoration of height close to average in this unique patient cohort should mitigate potential detrimental effects of short stature during childhood and allow for ageappropriate initiation of feminization. However, because the long-term efficacy and safety of such early treatment remains to be determined, a 10-yr study extension is underway, following the original cohort to adult height. Ϫ0 The models may be interpreted as follows: the first number in each model is the intercept; numbers in parentheses with explanatory variables are the parameter estimates for each variable. The variable parameter estimate represents the change of the dependent variable when the explanatory variable changes by one unit given that the other explanatory variables do not change. BA, Bone age; BH, baseline height; CA, chronological age; HV, height velocity; PRESS, predicted residual sum of squares (indicates predictive performance of the model; the smaller number, the better the predictive power of the model).
